653 related articles for article (PubMed ID: 11961977)
1. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
3. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
4. Function and expression of somatostatin receptors of the endocrine pancreas.
Strowski MZ; Blake AD
Mol Cell Endocrinol; 2008 May; 286(1-2):169-79. PubMed ID: 18375050
[TBL] [Abstract][Full Text] [Related]
5. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's).
Oberg K
Rocz Akad Med Bialymst; 2005; 50():62-8. PubMed ID: 16358941
[No Abstract] [Full Text] [Related]
7. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
[TBL] [Abstract][Full Text] [Related]
8. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders.
Ferone D; Resmini E; Boschetti M; Arvigo M; Albanese V; Ceresola E; Pivonello R; Albertelli M; Bianchi F; Giusti M; Minuto F
J Endocrinol Invest; 2005; 28(11 Suppl International):111-7. PubMed ID: 16625859
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease.
Höcker M; Wiedenmann B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S139-42. PubMed ID: 10604118
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin and its receptor family.
Patel YC
Front Neuroendocrinol; 1999 Jul; 20(3):157-98. PubMed ID: 10433861
[TBL] [Abstract][Full Text] [Related]
12. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603
[TBL] [Abstract][Full Text] [Related]
13. Future aspects of somatostatin-receptor-mediated therapy.
Oberg K
Neuroendocrinology; 2004; 80 Suppl 1():57-61. PubMed ID: 15477719
[TBL] [Abstract][Full Text] [Related]
14. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.
Guillermet-Guibert J; Lahlou H; Pyronnet S; Bousquet C; Susini C
Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):535-51. PubMed ID: 16183526
[TBL] [Abstract][Full Text] [Related]
15. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Grozinsky-Glasberg S; Grossman AB; Korbonits M
Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
De Martino MC; Hofland LJ; Lamberts SW
Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.
de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
Endocr Relat Cancer; 2003 Dec; 10(4):451-8. PubMed ID: 14713257
[TBL] [Abstract][Full Text] [Related]
19. The somatostatin receptor subtype 5 in neuroendocrine tumours.
van der Hoek J; Lamberts SW; Hofland LJ
Expert Opin Investig Drugs; 2010 Mar; 19(3):385-99. PubMed ID: 20151855
[TBL] [Abstract][Full Text] [Related]
20. Biology of somatostatin in breast cancer.
Watt HL; Kharmate G; Kumar U
Mol Cell Endocrinol; 2008 May; 286(1-2):251-61. PubMed ID: 18308465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]